Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074343 · ClinicalTrials.gov registry record · Phase 1
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
A Phase 1 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT04074343 is a Phase 1 study that has completed, run by University of California, Irvine. The registered enrollment target is 20 participants.
The verdict
NCT04074343, a Phase 1 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who are not candidates for curative treatments and who have received at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.
Interventions
- DRUG Irinotecan
- DRUG TAS-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2022-07-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04074343
The ClinicalTrials.gov registry entry for NCT04074343 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT04074343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04074343 about?
NCT04074343 is a clinical study titled "TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma". This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who are not candidates for curative treatments and who have received at least one prio...
What is the current status of trial NCT04074343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2019-08-26. Estimated completion is 2022-07-21.
What interventions are being tested in trial NCT04074343?
The interventions under investigation include: Irinotecan (DRUG), TAS-102 (DRUG).
Who is sponsoring clinical trial NCT04074343?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.